APA引文

Bruera, G., Pepe, F., Malapelle, U., Pisapia, P., Mas, A. D., Di Giacomo, D., . . . Ricevuto, E. (2018). KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy. Oncotarget.

Citação norma Chicago

Bruera, Gemma, Francesco Pepe, Umberto Malapelle, Pasquale Pisapia, Antonella Dal Mas, Daniela Di Giacomo, Giuseppe Calvisi, Giancarlo Troncone, and Enrico Ricevuto. "KRAS, NRAS and BRAF Mutations Detected By Next Generation Sequencing, and Differential Clinical Outcome in Metastatic Colorectal Cancer (MCRC) Patients Treated With First Line FIr-B/FOx Adding Bevacizumab (BEV) to Triplet Chemotherapy." Oncotarget 2018.

MLA引文

Bruera, Gemma, et al. "KRAS, NRAS and BRAF Mutations Detected By Next Generation Sequencing, and Differential Clinical Outcome in Metastatic Colorectal Cancer (MCRC) Patients Treated With First Line FIr-B/FOx Adding Bevacizumab (BEV) to Triplet Chemotherapy." Oncotarget 2018.